Quick Answer
Kymera Therapeutics, Inc. reported Operating Income of -$349.40 million for fiscal year 2025.
Kymera Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$349.40M | -33.5% |
| 2024 | -$261.63M | -58.1% |
| 2023 | -$165.53M | -2.7% |
| 2022 | -$161.26M | -60.4% |
| 2021 | -$100.53M | -117.1% |
| 2020 | -$46.30M | -9.7% |
| 2019 | -$42.20M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$92.52M | -28.3% | -9.4% |
| June 30, 2025 | -$84.56M | -66.0% | -13.6% |
| March 31, 2025 | -$74.43M | -28.7% | -3.2% |
| September 30, 2024 | -$72.12M | -25.4% | -41.6% |
| June 30, 2024 | -$50.92M | -17.4% | +11.9% |
| March 31, 2024 | -$57.83M | -27.6% | -0.6% |
| September 30, 2023 | -$57.51M | -28.1% | -32.6% |
| June 30, 2023 | -$43.38M | -6.3% | +4.3% |
- Kymera Therapeutics, Inc. showed a decrease of -33.5% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Kymera Therapeutics, Inc.’s operating income has declined by 727.9% (from -$42.20 million to -$349.40 million).
- The most recent figure is from Kymera Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: